Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 22322005 | HLA ASSOCIATED (HLA-ASSOCIATED) | drug hypersensitivity | NA | carbamazepine | NA | unclassified | |
| this study demonstrates a direct interaction of hla with drugs, provides a detailed molecular mechanism of hla-associated drug hypersensitivity, and has clinical correlations for cbz-related drug-induced sjs/ten. | |||||||
| 22348435 | HLA-B*15 | stevens-johnson syndrome | Chinese Han | carbamazepine | NA | unclassified | |
| association between hla and stevens-johnson syndrome induced by carbamazepine in southern han chinese: genetic markers besides b*1502? | |||||||
| 22348435 | HLA-A*31 | stevens-johnson syndrome | Chinese Han | carbamazepine | NA | negation | |
| previous studies have demonstrated a strong association between carbamazepine-induced stevens-johnson syndrome and toxic epidermal necrolysis (cbz-induced sjs/ten) and hla-b*1502 in chinese, and hla-a*3101 but not hla-b*1502 in caucasians and japanese. | |||||||
| 22348435 | HLA-B*15 | stevens-johnson syndrome | Chinese Han | carbamazepine | NA | negation | |
| previous studies have demonstrated a strong association between carbamazepine-induced stevens-johnson syndrome and toxic epidermal necrolysis (cbz-induced sjs/ten) and hla-b*1502 in chinese, and hla-a*3101 but not hla-b*1502 in caucasians and japanese. | |||||||
| 22689709 | HLA-B*15 | codeine | NA | carbamazepine | NA | unclassified | |
| NA | |||||||
| 22774598 | HLA-CLASS I (HLA-CLASS I) | stevens-johnson syndrome | Japanese | NA | NA | unclassified | |
| [hla-class i gene polymorphisms in japanese stevens-johnson syndrome patients with ocular surface complications]. | |||||||
| 22882221 | HLA-B*15 | stevens-johnson syndrome | NA | NA | NA | only_studied | |
| the specific mhc molecules implicated in hypersensitivity have been identified; for example, hla-b*5701 in abacavir-induced drug hypersensitivity and hla-b*1502 in carbamazepine-induced stevens-johnson syndrome. | |||||||
| 22882221 | HLA-B*15 | drug hypersensitivity | NA | NA | NA | only_studied | |
| the specific mhc molecules implicated in hypersensitivity have been identified; for example, hla-b*5701 in abacavir-induced drug hypersensitivity and hla-b*1502 in carbamazepine-induced stevens-johnson syndrome. | |||||||
| 22882221 | HLA-B*57 | stevens-johnson syndrome | NA | NA | NA | only_studied | |
| the specific mhc molecules implicated in hypersensitivity have been identified; for example, hla-b*5701 in abacavir-induced drug hypersensitivity and hla-b*1502 in carbamazepine-induced stevens-johnson syndrome. | |||||||
| 22882221 | HLA-B*57 | drug hypersensitivity | NA | NA | NA | only_studied | |
| the specific mhc molecules implicated in hypersensitivity have been identified; for example, hla-b*5701 in abacavir-induced drug hypersensitivity and hla-b*1502 in carbamazepine-induced stevens-johnson syndrome. | |||||||
Copyright 2024